Company History

    2016

Feb 2016Cell2in Inc. Established (CEO: Heun Soo Kang, Ph.D)
June 2016Certificated business affiliated laboratory (Korea Industrial Technology Association)
Certificated Venture company (Korea Technology Finance Corporation)
Sep 2016Korea Technology Finance Corporation Investment ($500,000)
Oct 2016Government R&D grant (Korea Ministry of SMEs and Startups, $100,000)
MTA Contract : Hanyang Univ. College of Medicine
Nov 2016MTA Contract : Seoul National Univ. College of Medicine, Konkuk Univ.
Dec 2016Government R&D grant (Korea Ministry of Health and Welfare, $2,900,000)
MTA Contract : Ulsan Univ. College of Medicine

    2017

Mar 2017Government R&D grant (IP-R&D, Korea Intellectual Property Office, $100,000)
Apr 2017BioKorea 2017 (Presentation of FreSHtracer platform technology)
May 2017MTA Contract : R company (Italy), K company
June 2017Patent application to Korea
July 2017Government R&D grant (Korea Ministry of Science and ICT, $3,000,000)
Patent application to (USA: 1, Korea: 2)
Joint Research Contract : M company
NDA/MTA Contract : R company
Aug 2017CKD Venture Capital Corporation Investment ($700,000)
Sep 2017Government R&D grant (Korea Ministry of trade, industry and energy, $400,000)
KSSCR 2017 (Presentation of FreSHtracer platform technology)
Oct 2017Start selling Research products of FreSHtracer
Nov 2017BioEurope 2017 (Presentation of FreSHtracer platform technology)
NDA Contract : T company (Spain)
Dec 2017Family company of Korea Research Institute of Bioscience & Biotechnology
NDA/MTA Contract : J company (Japan), DB company

    2018

Jan 2018Published in Stem Cell Report journal with FreSHtracer platform technology
Published in JCI journal with FreSHtracer platform technology
Certificated a special military service provider (Ministry of National Defense)
Reported to the Press  about FreSHtracer platform technology (Korea Health Industry Development Institute)
MTA Contract : Sookmyung Univ.
NDA contraction : B company (China), C company (Israel)
Joint Research Contract with H company
May 2018NDA Contract : D company
BioKorea 2018 (Presentation of FreSHtracer platform technology)
June 2018NDA contraction: A company (US)
ISSCR 2018 (Presentation of FreSHtracer platform technology)
Patent License Agreement Contract: D company
July 2018Patent License Agreement Contract: I company, J-ARM (Japan)
Patent application to a PCT
Joint Research Contract with the Catholic Unversity of Korea, College of Medicine
Aug 2018KSSCR 2018 (Presentation of FreSHtracer platform technology)
Sep 2018MTA Contract (NIST,USA-Korea))
International Joint Research Contract with Cellect, Israel
Oct 2018Government R&D grant (Korea Ministry of SMEs and startups, $450,000)
Government R&D grant (Korea Ministry of Health and Welfare, $1,500,000)
NDA contraction : K company (Japan)
Nov 2018Government R&D grant (Korea Ministry of SMEs and startups, $50,000)
International Joint Research grant with Cellect, Israel (Korea-Isrel Industrial R&D Foundation, $60,000)
Patent application to two PCT
Dec 2018Joint Research Contract of Animal disease Stem cell Therapy with C animal hospital
Honest Ventures Investment ($ 1,000,000)
Dong-Yu technology Corporation Investment ($1,000,000)

    2019

Mar 2019

Published in IJSC journal with Monitoring Glutathione Dynamics and Heterogeneity in Living Stem Cells

May 2019FreSHtracer technology Patent Registration to Korea(KR 10-1983803)
June 2019Clinical trials of cell therapeutic for diseased pets (C Animal Hospital)
Aug 2019Government R&D grant (Korea Small and Medium Business Administration, $15,000)

    2020

Apr 2020

Published in Sci Adv, J Clin Med, J Dermatol Sci  journal

FreSHtracer technology Patent Registration to USA (US 10,620,215)

May 2020Applying guidances for methods measuring the quality of stem cell therapies to US FDA

Cell quality improvement technique Patent Registration to Korea (KR 10-2119714)

May 2020Government R&D grant (Korea Ministry of SMEs and startups, $80,000)